STAT3 and head and neck squamous cell carcinoma: For example, AZD140 (JAK1/2 inhibitor) abrogated STAT3 activation and HNSCC tumor growth in a patient-derived xenograft preclinical model (257), but a study to assess the safety and tolerability of AZD140 as an oral monotherapy in patients with solid tumors (ClinicalTrials.gov #NCT01112397) (231) and a phase I study including GC in the expansion phase (ClinicalTrials.gov #NCT01219543) have both been terminated due to a decision to stop development of this JAK inhibitor (Table 1).